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Immune d eposits a t the cutaneous basement mem-
brane zone are a characteristic feature of systemic lupus 
erythematosus. Previous studies u sing immunofluores-
cent methods to detect complement components have 
provided evidence that some deposits contain immune 
complexes capable of activating complement. However, 
this important biologic property of complexes has not 
been detected or measured using functional assays, and 
it has not been determined whether immune deposits 
can activate complement at the basement membrane 
zone. 
In this study ~mmune deposits in biopsies oflupus skin 
have been examined u sing direct immunofluorescence 
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BMZ: basement membrane zone 
C3: third component of complement 
for the third component of complement (C3) to detect 
complement deposited in vivo. In addition, the deposits 
have been studied using the leukocyte attachment assay 
and indirect C3 binding immunofluorescence to detect 
and measure complement activation at the basement 
membrane zone in vitro. The results show that comple-
ment activation occurs at the basement membrane in 
some but not all lupus skin containing immunoglobulin 
deposits, that deposits differ quantitatively in their abil-
ity to activate complement, and that direct C3 immuno-
fluorescence is a relatively insensitive method for de-
tecting complement-activating complexes. The results 
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provide functional evidence suggesting that immune d e -
posits in some lupus skin are complement-activating 
complexes and potentially capable of activating comple-
ment at the basement membrane in vivo. Furthermore, 
the results suggest functional assays for evaluating com-
pleme nt-activating complexes may b e valuable supple-
ments to immunofluores cence in exploring the relation-
ship between immune deposits and systemic and cuta-
neous disease. 
Immunoglobulin d eposits at t he cutan eous basement m em-
brane zone (BMZ) are a characterist ic feature of systemic lupus 
erythematosus (SLE) . Alth ough there is evidence indicating 
th ey are immune complexes, t h eir functional biologic properties 
and pathologic significance remain relatively undefined [1,2]. 
Evidence th at th e deposits consist in part of complem ent -
activating immune complexes has been obtained using direct 
immunofluorescence to detect complem en t components [3- 6]. 
These studies have reported the third component of comple-
ment, C3, as well as componen ts of the classical, al ternative, 
and terminal complem en t pathways in som e but not all depos-
its. In those cases without complement, it h as been difficult to 
make judgments about the presence or a bsence of complem en t-
activating complexes. In a few cases, evidence for complem en t-
activating complexes has been obtained by d emonstrating com-
plement-binding antibodies in skin extracts [7]. With the excep-
tion of immunofluorescence a nd elution studies, no evidence for 
complement-activating immune complexes or activation of 
complem ent at the BMZ has been reported and no evidence for 
complem ent-activating deposits h as been obtained using 
methods to detect a nd m easure complem ent function. 
R ecently, we described a m ethod, the leukocyte attachment 
assay (LAA) to indirectly de tect and m easure complemen t 
activation by cu tan eous immune deposits in patients with bul-
lous pemphigoid [8-11]. Activation of complemen t in vitro by 
immune complexes deposited in vivo could be detected in 
cryostat sections of skin by t he complemen t -dependent , di-
rected migration and attachment of leukocytes to immune 
deposits. The m ethod could be quan t itated by m easuring the 
number of attached cells in fixed a nd stained sections. 
In this study, we h ave investigated immune deposits in SLE 
skin using th e LAA, indirect C3 binding immunofluorescence, 
and direct C3 immunofluorescence. The LAA and indirect C3 
binding h ave been used to detect a nd measure complem ent 
activation a nd deposition in vitro by immune r eactants depos-
ited at the BMZ in vivo. In addit ion , the results h ave been 
compared to direct C3 immunofluorescence which has been 
used to indicate in vivo deposit ion of complem ent-activating 
complexes. The results show that complem ent activation occms 
at the BMZ in some bu t not a ll SLE skin conta ining immuno-
globulin deposits, that deposits differ significantly in t he degree 
of complem en t activat ion, a nd that direct C3 immunofluores-
cence is a relatively insensitive method for detecting comple-
ment-activating complexes. These results provide functional 
evidence suggesting t hat immune deposits in SLE skin are 
complement-activating immune complexes and potentially ca-
pable of activating complement at the BMZ in vivo. Further-
more, t hey suggest the LAA and indirect C3 binding immuno-
fluorescence might be valuable supplem ents to direct immu-
nofluorescence in exploring the func t ional relationship between 
BMZ immune deposits and systemic and cutaneous disease. 
MATERIALS AND METHODS 
SLE Shin 
T wenty-nine, 3- to 4-mm punch biopsies from 21 patients with SLE 
were selected for this study from a supply of t issue previously submitted 
for routine diagnostic direct immunofluorescence. AU biopsies had a 
positive lupus band test and were from patients who met at least 4 of 
the American Rheumatism Association's criteria for the classification 
of SLE [12]. The biopsies had been obta ined under local Xylocaine 
anesthesia, fresh-frozen in Liquid ni trogen, mounted in Ames O.C.T. 
compound (Ames Co., Elkhart, Indiana) , and stored frozen at -70°C 
for less than 18 months. Of the 29 biopsies, 4 were from lesional skin, 
11 from sun-exposed nonlesional skin, and 14 from unexposed nonle-
sional skin. The biopsies were obtained from both treated a nd untreated 
patients at various stages of disease duration and severity. 
Control Shin 
Two control groups consisted of 23, 3- to 4-mm punch biopsies of 
skin; 9 were biopsies from healthy volunteers (normal human control 
group, NHC) and 14 were biopsies of lesional skin ti·om patients with 
a variety of inflammatory skin lesions not associated with immune 
deposits at the BMZ (disease control group, DC). Include d in the DC 
group were 5 patients with eczema, 2 with hypersensitivity vasculi tis, 
2 with erythema multiforme, and 1 each wit h urticarial vasculit is, 
papular dermatitis of pregnancy, Sweet's syndxome, dermatomyositis , 
and immunofluorescent-negative chronic bullous disease of childhood. 
All biopsies were processed and stored as noted for SLE biopsies. 
Serum Complement 
Fresh-frozen, platelet-poor normal human serum (NHS) from a 
single blood group AB, type RH-positive donor was used as a source of 
serum complement in all studies. Blood was collected under sterile 
conditions and fresh platelet-poor serum prepared as previously de-
scribed [8]. NHS was divided into 0.5-ml aliquots and stored frozen at 
-70°C. Some aliquots were heat inactivated at 56°C X 30 min (NHSi) 
and used as a complement control. AU dilutions of NHS and NHSi 
were made in Gey's balanced salt solution (GBSS) containing 2% bovine 
serum albumin. 
Peripheral Blood Leu.hocytes (PBL) 
PBL ti·om normal donors were prepared by dextran sedimentation 
of heparinized whole blood [8]. Following dextra n sedimentation for 30 
min at 25°C, the leukocyte-rich supernate was remove d and cells 
washed x 2 in GBSS. Residual red blood cells were not lysed. Total 
leukocytes and cell viability were determined by counting t rypan blue-
stained cells in hemocytometer. Viabili ty was consistently greater than 
98%. T he percentage granulocytes to tota l leukocytes was 70-85%. Prior 
to use, PBL were adjusted to 10 X 10" cells/ ml in either 10% NHS or 
10% NHSi. 
Immunofluorescent Techniques 
Direct immunofluorescence fo r IgG , IgA, IgM , and C3 was performed 
on 6 !IDl-thick cryostat sections of skin using t he method of Beutner 
and Nisengard [13]. Indirect C3 binding immunofluorescence was per-
form ed by incubating 6 f.Lm-thick cryostat sections of SLE skin with 
25% NHS or NHSi as control at 37°C for 30 min followed by 3 5-min 
rinses in 0.15 M NaCl buffered with 0.01 M NaHPO., and 0.1 M NaH2PO.,, 
pH 7.2 (PBS). Following the final rinse, sections were stained fo r C3 
[14]. All antisera were flu orescein isothiocyanate(FITC)-conj ugated 
goat antisera to human proteins puJ·chased from Cappel Labs, Coch-
ranville, Pennsylvania. Specific anti body concentrations and molar 
flu orescein to protein ratios weJ·e: anti-IgG, 6.1 mg/ ml and 2.5; anti-
IgM, 2.5 mg/ml and 3.4; anti-IgA, 3.0 mg/ml and 3.0; anti-C3, 3.0 mg/ 
ml and 3.2. AU antisera were used at a working dilution of 1:10 in 
phosphate-buffered saline (PBS). Immunofluroescence was read on a 
Leitz Orthoplan microscope equipped with epi-illumination and·appro-
priate exciter and barrier filters. Results of indhect C3 binding immu-
nofluorescence were in terpreted as positive if t here was a significant 
increase in C3 immunofluorescence compared to direct C3 immuno-
flu orescence. 
Leukocyte Attachment Assay 
T he LAA was perfo rmed by modification of a previously described 
technique [8,15]. Three to four 6 f.Lm-thick cryostat sections from each 
biopsy were placed in the center of gelatin-coated glass s lides, dried 
briefly at 25°C, and rinsed for 5 min in cold PBS. The slides were 
allowed to dry again and were covered with a second slide with 2 
th icknesses of vinyl tape (Fisher Scientific Company) attach ed to each 
end. The tape prevented the covering slide ti·om making di.t"ect contact 
with tissue and formed a chamber between the slides 0.2 mm-thick and 
0.3 ml in volume. The slides were clamped together and injected with 
0.3 ml of 10 X 106 PBL/ ml in either 10% NHS or 10% NHSi. Chambers 
were incubated for 37°C X 30 min in a humidified air incubator, 
disassembled, and nonadherent cells and serum removed by e. 10-min 
rinse in PBS. Slides were dried briefly at 25°C, fixed in 100% ethanol, 
and stained with hematoxylin and eosin. T he LAA was performed on 
each biopsy in duplicate or triplicate and results averaged to obtain a 
LA value for each biopsy. 
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TABLE l. Immunofluorescence results in systemic lupus 
erythematosus shin 
Biopsy Number Biopsy site IgG lgA lgM C3 C3 binding 
11" L + + 0 0 + 
12 u + + 0 0 + 
21 L + + 0 0 + 
22 u + + 0 0 + 
31 u + + + + + 
32 E + + + + + 
41 E + + + + + 
42 u + + + + 0 
51 u + + + + + 
52 u 0 0 0 0 o" 
61 E + 0 + + + 
'71 L + + + + + 
81 u + 0 + + 0 
91 E + + 0 0 o" 
101 E 0 0 0 0 O'' 
111 u + 0 0 0 o" 
121 E 0 + 0 0 O'' 
122 u 0 + 0 0 o" 
131 E + 0 0 0 o" 
141 u · + 0 0 0 O" 
142 L + 0 0 0 + 
151 u + 0 0 0 0 
161 E + + + + 0 
171 u + + + + O" 
181 E + 0 0 0 o" 
191 u + 0 0 0 O'' 
201 E + 0 0 0 0'' 
211 E + 0 0 0 o" 
212 u + 0 0 0 + 
L = Lesional skin; E = normal sunexposed skin; U = unexposed skin; 
+ = present; 0 = a bsent. 
"The underlined numbers 1-21 refer to the 21 separate patients. 
"Biopsies in which C3 binding could be unequivocaLly excluded. 
Quantitation of LA 
Each slide was examined at 4oox using a light microscope equipped 
with a lOX filar linear micrometer e"yepiece (American Optical Corp., 
Buffalo, New York). Attachment was quantitated by counting the 
number of PBL/mm of BMZ in 6-8 random fields per 3-4 sections and 
divided by the number of fields. A mean LA value ± SD was calculated 
for each bicpsy by averaging LA values in duplicate or triplicate assays. 
Statistica l analysis of results were computed by t-test. 
RESULTS 
Direct Immunofluorescence of SLE Shin Biopsies 
The results of direct immunofluorescence in SLE biopsies are 
shown in Table I. In all biopsies, deposits of 1 or more Ig classes 
with or without C3 were observed in a stippled, granular, or 
homogeneous pattern. Of the 29 biopsies, IgG and IgM were 
each present in 25 and IgA in 14. Eleven biopsies contained all 
3 Ig classes, 13 contained 2 Ig classes, and 5 contained 1 class. 
C3 was observed by direct immunofluorescence in 10 of 29 
biopsies. Although no attempt was made to grade the intensity 
of C3 or immunoglobulin immunofluorescence, there was con-
siderable variation present. 
Indirect C3 Binding Immunofluorescence in SLE Biopsies 
The results of indirect C3 binding in SLE biopsies are shown 
in Table I. Binding of exogeneous (NHS) C3 to the BMZ at 
sites of lg deposition was observed in 12 of the 29 biopsies, from 
9 of 21 patients. Of those 12, 6 showed no C3 on direct immu-
nofluorescence (Fig 1). The remaining 6, although positive for 
C3 by direct immunofluorescence, showed a definite increase in 
the intensity of C3 staining after incubation with NHS. In 
controls incubated with NHSi, no C3 deposition was observed. 
In biopsies that contained C3 deposits by direct immunofluo-
rescence but did not show an increase in C3 binding, we could 
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FIG 1. Example of indirect C3 binding immunofluorescence in SLE 
biopsy no. 11 . Top, Direct C3 immunofluorescence showing no C3 
deposits. Bottom, Same skin pretreated for 30 min at 37°C with 25% 
fresh NHS and subsequently incubated with FITC-conjugated antihu-
man C3. 
TABLE II. Leullocyte attachment in systemic lupus e1ythematosus 
shin 
LA (PBL/ mm BMZ ± SO) 
Biopsy number 
With 10% NHS With 10% NHSi 
11 161 ± 35 67 ± 13" 
12 142 ± 24 58± 8" 
21 146 ± 46 46 ± 16 
22 130 ± 20 57± 9" 
31 135 ± 20 61 ± 10" 
32 125 ± 23 74 ± 13" 
41 84 ± 7 54± 8" 
42 88 ± 6 65 ± 8" 
51 133 ± 28 59± 6" 
52 24 ± 4 28 ± 4 
61 107 ± 24 60 ± 9" 
71 124 ± 24 60 ± 13" 
81 76 ± 14 43 ± 9 
91 30 ± 6 32 ± 9 
101 40 ± 6 60 ± 10" 
111 20 ± 6 47 ± 3 
121 54± 14 75 ± 18" 
122 27 ± 6 26 ± 7 
131 27 ± 4 26 ± 4 
141 38 ± 4 52± 7" 
142 75 ± 7 53± 5" 
151 76 ± 5 43 ± 5 
161 158 ± 18 99 ± 13" 
171 77 ± 6 39 ± 2 
181 16 ± 2 41 ± 3 
191 85 ± 6 26 ± 4 
201 32 ± 4 20 ± 3 
211 71 ± 8 50± 5" 
212 100 ± 11 13 ± 2 
" LA greater than DC + 2 (SD) 
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Requirements for NHS in LA 
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FIG 2. Results of the LAA in systemic lupus erythematosus (SLE), 
normal human {NH), and disease contro l {DC) skin. Hat ched columns 
show the means for each group ± SD. The solid horizontal line 
represents the mean LA+ 2 X SD for the DC group. The closed circles 
represent LA values for the 29 SLE biopsies. Note that LA values in 20 
SLE biopsies were above the mean LA + 2 x SD of the DC group. 
not, of course, exclude the possibility that additional C3 may 
have been bound. This was particularly true in biopsies with 
relatively intense direct C3 immunofluorescence. However, in 
13 biopsies (nos. 52, 91- 142, 181-211) we could unequivocally 
exclude (within the sensitivity of the method) C3 binding since 
C3 was not observed by either direct or indirect C3 immuno-
fluorescence . 
Leulwcyte Attachment in SLE Biopsies 
The results of the LAA in the 29 SLE biopsies are shown in 
Table II and Fig 2. An example of LA in biopsy no. 11 is shown 
in Fig 3. When the LAA was performed with 10% fresh NHS, 
a wide (10-fold) range of LA values was observed. T he lowest 
value was 16 ± 2 and the highest 161 ± 35. The results of LA in 
individual biopsies were reasonably reproducible with SD rang-
ing from 7-32%. The mean SD for all 29 biopsies was 16%. In 
general, the higher LA values had greater SD. The mean LA 
± SD for the entire group of SLE biopsies was 83 ± 45 which 
was significantly greater than either of the control groups, NRC 
and DC (p < .05) . No difference was observed in mean LA 
between the 2 control groups. An analysis of the distribution of 
LA in SLE biopsies (Fig 2) showed that 20 of the 29 (69%) 
biopsies from 15 of 21 patients were significantly elevated above 
the mean + 2 SD (48 PBL/mm BMZ) of control group DC. 
These biopsies were considered to have significantly elevated 
LA values. 
The data on LA in SLE biopsies were also analyzed on a per 
patient basis by averaging the results of LA in those patients 
with more than 1 biopsy (data not shown) . The mean LA for 
the 21 SLE patients was 77.8 and this value was still signifi-
cantly greater (p < .05) than LA in the NHC and DC groups. 
By averaging LA in each SLE patient 14/ 21 had a LA value 
greater than 48 PBL/mm BMZ. 
To demonstrate a requirement for serum complement the 
LAA was performed on SLE biopsies using PBL suspended in 
fresh NHS or NHSi. The results (Table II) showed a reduction 
in LA in 22 of the 29 SLE biopsies. In the 20 biopsies with LA 
values greater than control + 2 SD, 19 (95%) showed greater 
attachment with NHS than with NHSi (Fig 4). In this group of 
20 biopsies, the mean LA with NHS was 107 ± 32 compared to 
55 ± 18 with NHSi. This difference was highly significant (p 
< .001 level). Interestingly, LA in a number of SLE biopsies 
(Table II), although decreased with NHSi, was still significantly 
elevated above control. 
FIG 3. Leukocyte attachment in SLE biopsy no. 11. Note the non-
random linear distr ibution of PBL in the upper dermis beneath the 
BMZ (arrow). 
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Frc 4. A comparison of LA performed with NilS and NHSi. The 
circles on the left represent elevated LA values in 20 SLE biopsies 
obtained with PBL in fresh NHS. Circles on the right are the corre-
sponding values obtained with PBL suspended in heat-inactivated 
NHS. 
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Correlation Between LA and Indirect C3 Binding 
Immunofluorescence in SLE Shin 
There were 12 biopsies with indirect C3 binding immunofluo-
rescence. There were, in addition, 13 biopsies in which C3 
binding could be excluded, i.e., C3 was not observed by direct 
or indirect immunofluorescence (Table I). In the 12 biopsies 
with C3 binding, LA values in all (100%) were elevated (greater 
than control LA + 2 SD). In the 13 biopsies with unequivocal 
absence of C3, elevated LA was seen in only 4 (31 %) . The mean 
LA for the 12 SLE biopsies with indirect C3 binding was 122 
± 24 compared to 55 ± 35 in the remaining 17 biopsies without 
C3 binding and 41 ± 22 in the 13 biopsies with unequivocally 
negative C3 binding. These differences were highly significant 
(p < .001level). 
Results of LA and Indirect C3 Binding Immunofluorescence 
in SLE Biopsies With and Without In Vivo Deposited C3 
There were 10 biopsies with in vivo deposited C3 as shown 
by direct C3 immunofluorescence. The mean LA for these 
biopsies was 110.6 ± 26.8. In the 19 biopsies without C3 deposits, 
LA was 68 ± 46. This difference, although large, was not 
significant (p > .05) . Of the 10 biopsies with direct C3 immu-
nofluorescence all showed elevated LA values and 6 showed C3 
binding. Of special interest was the observation that in the 19 
biopsies with negative direct C3 immunofluorescence, 10 (53%) 
showed elevated LA and 5 (26%) showed indirect C3 binding. 
R elationship Between Indirect C3 Binding and LA and the 
Number of Ig Classes Deposited 
There were 11 of 29 (38%) biopsies with deposits of all 3 Ig 
classes (IgG, IgA, and IgM). Among these, 9 (82%) showed 
indirect C3 binding and 10 (91%) elevated LA. Ofthe 13 biopsies 
with 2 Ig classes, C3 binding was present in 2 (15%) and elevated 
LA was observed in 9 (69%). Of the 5 biopsies with 1 Ig class, 
none had C3 binding and only 1 (20%) showed elevated LA. 
Although the intensity of immunofluorescence was not re-
corded, our impression was. that there was a positive but im-
perfect correlation between intensity of lg staining, number of 
lg classes present, and results of indirect C3 binding and LA. 
However, we could appreciate no correlation between the in-
tensity of direct C3 immunofluorescence and LA. 
DISCUSSION 
Prior to this study, evidence for complement-activating im-
mune complexes in SLE skin was based almost entirely on 
direct immunofluorescence for immunoglobulin and comple-
ment deposits. Studies have reported immunoglobulin in 60-
100% of active skin lesions and in 25-75% of nonlesional skin 
[1,2,16]. Complement (C3) deposits have been reported in 30-
100% of biopsies containing immunoglobulins but rarely in their 
absence. In addition to C3, components of the classical (Clq, 
C4), alternative (factors B, P, and H), and terminal (C5, C5b-
C9 membrane attack complex) complement pathways have 
been reported [3-6]. Additional support for cutaneous deposi-
tion of complement-activating immune complexes was obtained 
in one study which eluted complement-binding antinuclear 
antibodies from skin of 2 patients [7]. 
In this study, evidence for complement-activating complexes 
at the BMZ was obtained by indirect C3 binding immunofluo-
rescence and/or the LAA in 20/29 biopsies with Ig deposits 
from 15/ 21 SLE patients. Both methods appeared to detect 
complement deposition or activation in vitro by immune reac-
tants deposited at the BMZ in vivo. Activation of complement 
was supported by a requirement for fresh serum for indirect C3 
binding and maximal LA. The deposition of C3 and attachment 
of leukocytes at the site of Ig deposits and the significantly 
greater LA in SLE compared to control skin provided evidence 
that immune deposits were the cause of complement activation. 
Although LA appeared to be largely dependent on comple-
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ment activation in vitro, several observations suggested that in 
some biopsies there was a direct interaction between leukocytes 
and immune reactants deposited in vivo. For example, LA was 
elevated in 4 biopsies (nos. 121, 142, 191, 211) with unequivo-
cally negative C3 binding. In addition, when the LAA was 
performed with heat-inactivated serum which should prevent 
complement activation by the direct or alternative pathways, 
LA was still elevated above control in several biopsies. Attach-
ment in those cases could have been due to immune adherence 
(attachment via leukocyte receptors for immunoglobulin Fe 
and/or complement) to immune reactants deposited at the 
BMZ in vivo [17]. Regardless of the cause, the extent of attach-
ment due to mechanisms other than complement activation 
could be estimated by performing the LAA with both fresh and 
heat-inactivated serum. The excellent correlation between re-
sults of the LAA and indirect C3 binding further supported 
complement activation as a major cause of attachment. 
Although indirect C3 binding immunofluorescence and the 
LAA appeared to detect complement activation, the latter 
method seemed to offer several advantages. First, the LAA 
could be quantitated by counting cells, a feature which we feel 
is less subjective than assessing the "intensity of immunofluo-
rescence." This feature should be of value in distinguishing 
differences in the degree of complement activation among biop-
sies with indirect C3 binding. The range of LA values was 16-
161 (mean 145) for all SLE biopsies and 75-161 (mean 85) for 
biopsies with indirect C3 binding. Secondly, activation of com-
plement in biopsies with in vivo deposited C3, particularly those 
with intense C3 deposits, may not be detectable by indirect C3 
binding immunofluorescence. In this study there was signifi-
cantly elevated LA in the presence of fresh NHS in 4 biopsies 
with positive direct and negative indirect C3 binding. This 
suggests complement was activated in these biopsies but that 
insufficient C3 was deposited in vitro to be detectable over 
"background" C3 deposited in vivo. 
Both the LAA and indirect C3 binding seemed s.uperior to 
direct C3 immunofluorescence in providing evidence for com-
plement-activating deposits at the BMZ. This was suggested by 
a poor correlation between the methods, which was due mainly 
to positive indirect C3 binding and LA in biopsies with negative 
direct C3 immunofluorescence. Although all biopsies with pos-
itive direct C3 immunofluorescence had elevated LA and most 
had positive indirect C3 binding, a significant number of biop-
sies with negative direct immunofluorescence had elevated LA, 
indirect C3 binding, or both. This finding suggests that negative 
direct C3 immunofluorescence does not exclude the presence of 
complement-activating complexes. This has previously been 
suggested by studies reporting Clq in lupus skin and the C5b-
C9 membrane attack complex in lupus kidneys in the absence 
of C3 [ 4,18]. The absence of detectable C3 in deposits capable 
of activating complement is not readily explainable but may be 
due to limited or absent complement activation in vivo due to 
inhibitors, low complement component levels, poor access of 
complement components to the BMZ, or a short half-life for 
C3. A short half-life could be due to the absence of a receptor 
for C3 and/or rapid degTadation [18-20]. 
Evidence that cutaneous immune deposits may not be capa-
ble of activating complement was also obtained in this study. 
In 9 biopsies from 9 SLE patients, we observed no complement 
deposition or activation by direct or indirect C3 binding im-
munofluoTescence or the LAA. In general, these were biopsies 
with only 1 or 2 immunoglobulin classes present. Although we 
did not attempt to "quantitate" the intensity of immunofluo-
rescence, our impression was that biopsies that failed to show 
complement activation or deposition tended to have relatively 
less intense immunoglobulin immunofluorescence and fewer Ig 
classes deposited. A correlation between intensity of immuno-
fluorescence and numbers of lg classes deposited has been 
reported previously [21]. Since most antibodies tend to be 
heterogeneous in their ability to activate complement, it is not 
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surprising that, in some cases, noncomplement-activating im-
mune reactants may be deposited in skin . 
M ethods for detecting and quantitating complemen t-activat-
ing immune deposits in SLE skin may be valuable in studying 
their relationship to systemic and cutaneous disease. There is 
abundant evidence that complement-activating complexes play 
an important role in tissue da mage in SLE. Likewise, there is 
evidence, though disputed, that cutaneous immune deposits 
may be involved in the pathogenesis of skin lesions and/or 
reflect the pathologic potential of circulating complexes or 
complexes deposited in other organs. There are a number of 
reports of an association between the presence of cutaneous 
immune deposits and the severity of systemic disease, severe 
nephritis, hypocomplementemia, circulating autoantibodies (in-
cluding complement-binding antibodies) to DNA and skin le-
sions [5,6,22-28]. The significance of these reports has been 
questioned by a number of studies that have failed to find these 
associations [29-32]. In none of the studies investigating the 
relationship between cutaneous deposits and systemic and cu-
taneous disease have attempts been made to measure or select-
ively distinguish complement-activating and noncomplement-
activating cutaneous deposits. This type of functional hetero-
geneity probably exists as suggested in this study. Perhaps the 
application of methods described in this report to the investi-
gation of cutaneous immune deposits in SLE could help clarify 
their functional relationship to systemic and cutaneous disease. 
Although the relevance of complement-activating immune 
complexes and the LAA to the pathogenesis of skin lesions are 
important issues, they cannot be determined from om studies. 
The interactions between complexes, serum complement, and 
PBL in the assay closely resemble those involved in the Arthus 
reaction [9,10], while the histology of most lesions resembles a 
cell-mediated immune response [33,34]. This difference plus 
the fact that the LAA was positive in clinically (and probably 
histologically) normal skin show quite clearly that it is not a 
literal representation of in vivo mechanisms of lesion production 
whatever they may be. Although the mechanism of the LAA 
does not seem to be involved in lesion production, this does not 
exclude a role for complement-activating immune complexes. 
It is clear that activation of the terminal complement pathway 
on or near tissue cells can cause damage independent of inflam-
matory cells and it has been reported that the C5-9 membrane 
attack complex is present in the immune deposits in skin lesions 
but not in the deposits in nonlesional skin (6]. It is also possible 
that complexes and complement may be involved in the inflam-
matory response since they can interact with both monocytes 
and lymphocytes [35,36]. In some animal models of immune 
complex disease, lymphocytes and monocytes are the most 
common cells found, particularly in the late stages of inflam-
mation [37]. Therefore, even though the mechanism of LA may 
not be pertinent to the development of lesions, the fact that it 
can detect complement activating complexes may be. 
It is, of cow·se, unknown why complexes in lupus skin may 
mediate an Arthus-like reaction in vitro but not in vivo. The 
reasons may be due to the altered condit~ons that exist in the 
LAA. In the assay, tissue is freeze-thawed, cut, and exposed to 
buffers, NHS, and to "processed" leukocytes from normal do-
nors. Such treatment could result in removal of natural tissue 
inhibitors of complement activation, chemotactic factors, and 
leukocyte migration, alter the activity or availability of comple-
ment components, and disturb the microenvironment of the 
BMZ in such a way as to reveal latent complement-activating 
potential. Furthermore, PBL are virtually "dropped" on the 
BMZ in vitro and probably have fewer physiologic obstacles to 
migration. It is also possible that the defective leukocyte che-
motaxis of SLE granulocytes and the poor generation of com-
plement-derived chemotactic activity in SLE serum could in-
terfere with the development of the Arthus-like reaction in vivo 
(38-40]. Further resolution of these questions will require new 
techniques to determine the degree of complement activation 
in tissue in vivo, and to what extent the LAA is an accmate 
indicator of in vivo complement activation. 
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Influence of Langer hans Cells on the Survival of H-Y Incompatible Skin 
Grafts in Rats 
HoNe-Duo CHEN, M.D. * AND WILLYS K. SILVERS, PH.D. 
Department of Human Genetics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A. 
Evidence is presented that Langer hans cells (LCs) play 
an important role in the rejection of H-Y incompatible 
skin grafts in BN rats. Not only are small male trunk 
skin isografts much more likely to be rejected by BN 
females than similarly sized male foot pad, tail, and ear 
skin transplants, all of which possess fewer LCs than 
trunk skin, but the survival of male trunk skin grafts 
can be prolonged by replacing their LC population with 
allogeneic female cells. 
In rats, as in mice, there is a weak transplantation antigen-
known as the H-Y antigen-associated with theY chromosome 
(1]. As a consequence, females may reject skin grafts from male 
donors of the same inbred strain. Their ability to do so depends 
upon a number of factors including their genotype and the size 
of the graft [2,3). Small grafts are more likely to be rejected 
than large grafts. The survival of H- Y incompatible skin grafts 
also depends upon their origin. This is especially the case in 
BN rats when~ small male trunk skin grafts are usually rejected 
within 50 days, while similarly sized grafts .of ear or tail origin 
frequently survive >100 days [3). This situation also occurs in 
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mice, though the differences are much less pronounced. In 
C57BL/6 mice, male tail and ear skin isografts persist a little 
longer on female than male trunk skin grafts of the same size 
[ 4]. Recently, it has been suggested that the better survival of 
H-Y incompatible mouse tail skin grafts as compared with 
those of trunk skin may result from their paucity of Langer hans 
cells (LCs). Thus; Bergstresser and his colleagues [5] suggest 
that "Langer hans cell-poor skin may be lacking certain essential 
functions relating to the induction and expression of immune 
reactivity." The following investigation provides further evi-
dence for this contention. Indeed, not only have we found that 
there is a con-elation between LC density and the smvival of 
different kinds of H-Y incompatible skin grafts in rats, but we 
have been able to prolong the survival of H -Y incompatible 
trunk skin grafts in this species by replacing their LC population 
with allogeneic female cells. 
MATERIALS AND METHODS 
Animals 
The major histocompatibility complex (MHC) incompatible BN/ Ss 
(BN) and Lewis/ Ss (Lew) rats employed in this study, as well as their 
F1 hybrids (Lew/ BN), were domestically produced. 
Abbreviations: 
BN: BN/Ss rats 
LC: Langerhans cell 
Lew: Lewis/ Ss rats 
Lew/ BN: (Lewis X BNlF1 hybrid rats 
MHC: major histocompatibility complex 
MST: median survival time 
PBS: phosphate-buffered saline 
SOF: sole of foot 
